Welcome to our Q2 presentation, and thank you for joining us today in the middle of the Swedish summer. We have concluded a busy quarter with high activity in all markets, achieving increased order intake and securing deals despite market uncertainty. As many of you know, the foundation of our offering is the demand and need for safer cancer treatments with a focus on the patient's quality of life. And it's also about increasing efficiency in the customers' clinics. And we are on a journey.
We are building an even stronger company, working hard on our financial strengths so that we can access both established and untapped markets globally with our world-leading products and services. So now let's take a look at the Q2 performance and the key takeaways.
Q2 was indeed a busy quarter, and we are taking steps towards our financial targets.
And I am pleased that the hard work done by the team driving marketing activities, participating in trade shows, and organizing reference site visits, which is common in the final phase of the customer buying process, is paying off. We took a number of larger deals in both the US and EMEA in the second quarter.
Our order intake grew by 11% in constant currencies. The main contribution came from EMEA and the Americas, and we ended the quarter with a strong order backlog of 735 million SEK. And when looking at the backlog, approximately half of the order backlog consists of products and the other half of service contracts, which are typically 3 to 5 years. And this does, of course, provide good recurring revenue. Invoiced at the start of each quarter, revenue year on year declined by 13% in constant currencies, and the main reason is a softer order intake during 2024.
And it's also worth noting that Q2 last year was boosted by approximately 20 million SEK of China deliveries due to the product registration approval, and the weaker top line had a direct impact on EBIT. And we came in with a moderate 8 million SEK. However, we have a stable gross margin, and Linda will share more soon.
Our EBIT margin in the quarter was 8%. We are improving operational efficiency step by step and have reduced OpEx by 10% compared to Q2 last year.
And the focus on cost efficiency is now part of our DNA, which means that we are continuously driving both cost control and implementing measures to streamline operations. And that said, we have more work to do. So let's look into the regional performance in the quarter.
And I'll start off with the Americas.
And our long-term focus is to strengthen our position in the US market. And we made good progress this quarter despite uncertainty in the US market. And this is mainly due to tariffs. The two large orders in the quarter that we are showing here on the slide represent different aspects of our untapped opportunity. The product order to a prominent Proton facility is for bunkers in their newly built satellite facility, and I am delighted that this existing customer decided to expand their footprint with us. The other large order is a pure service contract with a renowned cancer center on the East Coast.
And this is a renewal which is important to us, and it's a clear indication of the strength of our offering and our focus on customer retention. Order intake for the Americas increased by 11% to 31 million in Q2, and revenue grew by 26% in the quarter. Moving over to EMEA, the hard work by the team is paying off in the quarter.
We have good momentum, and we were rewarded with an 8.5 million SEK strategic multi-site product and services contract in France with the leading private care provider, Ronce Santé Group. And we are motivated by this, as France is a market where we are coming from a challenger position.
We can also see signs of recovery in the important German market, and I am pleased that we received a 9 million SEK product and service contract from one of the most important healthcare providers in the dynamic Stuttgart region in southern Germany.
Order intake increased 47% to 46 million, and revenue in EMEA was down 11% to 43 million.
Still impacted by a lower order intake during last year.
And finally, APAC had a softer second quarter. Q2 last year was fueled by a vital boost. Order intake benefited from the earlier Japanese market launch at the end of 2023. However, APAC is still our largest market, and there is untapped demand in advanced markets as well as the large developing markets in the region.
We have a healthy market mix and see an increasing uptake of SGRT, and it's starting to become a given in the clinical workflow.
Order intake declined 15% to 58 million, and revenue in APAC decreased by 34% to 44 million in Q2. And as I mentioned earlier, it's impacted by strong China deliveries last year. And if we adjust for these deliveries, APAC had a 1% growth in constant currencies.
And with that, over to you, Linda. For a closer look at the financials.